232 related articles for article (PubMed ID: 28000524)
1. Modulation of cancer-specific immune responses by amino acid degrading enzymes.
Timosenko E; Hadjinicolaou AV; Cerundolo V
Immunotherapy; 2017 Jan; 9(1):83-97. PubMed ID: 28000524
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy.
Brochez L; Kruse V; Schadendorf D; Muller AJ; Prendergast GC
Front Immunol; 2021; 12():789473. PubMed ID: 34938297
[No Abstract] [Full Text] [Related]
4. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
[TBL] [Abstract][Full Text] [Related]
5. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
7. Evading immunity: new enzyme implicated in cancer.
Garber K
J Natl Cancer Inst; 2012 Mar; 104(5):349-52. PubMed ID: 22349199
[No Abstract] [Full Text] [Related]
8. Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan.
van Baren N; Van den Eynde BJ
Cancer Immunol Res; 2015 Sep; 3(9):978-85. PubMed ID: 26269528
[TBL] [Abstract][Full Text] [Related]
9. Immune-suppressive properties of the tumor microenvironment.
Becker JC; Andersen MH; Schrama D; Thor Straten P
Cancer Immunol Immunother; 2013 Jul; 62(7):1137-48. PubMed ID: 23666510
[TBL] [Abstract][Full Text] [Related]
10. Role of tryptophan metabolism in cancers and therapeutic implications.
Liu XH; Zhai XY
Biochimie; 2021 Mar; 182():131-139. PubMed ID: 33460767
[TBL] [Abstract][Full Text] [Related]
11. The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO.
Mondanelli G; Ugel S; Grohmann U; Bronte V
Curr Opin Pharmacol; 2017 Aug; 35():30-39. PubMed ID: 28554057
[TBL] [Abstract][Full Text] [Related]
12. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
Front Immunol; 2022; 13():807271. PubMed ID: 35173722
[TBL] [Abstract][Full Text] [Related]
13. [A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase].
Van den Eynde B
Bull Mem Acad R Med Belg; 2003; 158(7-9):356-63; discussion 364-5. PubMed ID: 15132006
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine tumours and their microenvironment.
de Hosson LD; Takkenkamp TJ; Kats-Ugurlu G; Bouma G; Bulthuis M; de Vries EGE; van Faassen M; Kema IP; Walenkamp AME
Cancer Immunol Immunother; 2020 Aug; 69(8):1449-1459. PubMed ID: 32270230
[TBL] [Abstract][Full Text] [Related]
15. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
Amobi A; Qian F; Lugade AA; Odunsi K
Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of targeting tryptophan catabolism in cancer.
Opitz CA; Somarribas Patterson LF; Mohapatra SR; Dewi DL; Sadik A; Platten M; Trump S
Br J Cancer; 2020 Jan; 122(1):30-44. PubMed ID: 31819194
[TBL] [Abstract][Full Text] [Related]
17. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
18. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
20. Amino-acid sensing and degrading pathways in immune regulation.
Grohmann U; Mondanelli G; Belladonna ML; Orabona C; Pallotta MT; Iacono A; Puccetti P; Volpi C
Cytokine Growth Factor Rev; 2017 Jun; 35():37-45. PubMed ID: 28545736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
